Quantum Biopharma Stock Price Prediction
| QNTM Stock | 4.01 0.07 1.72% |
Oversold Vs Overbought
31
Oversold | Overbought |
EPS Estimate Current Year (14.30) | EPS Estimate Next Year (7.80) | Wall Street Target Price 169 |
Using Quantum BioPharma hype-based prediction, you can estimate the value of Quantum BioPharma from the perspective of Quantum BioPharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Quantum BioPharma using Quantum BioPharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Quantum using crowd psychology based on the activity and movement of Quantum BioPharma's stock price.
Quantum BioPharma Implied Volatility | 1.89 |
Quantum BioPharma's implied volatility exposes the market's sentiment of Quantum BioPharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Quantum BioPharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Quantum BioPharma stock will not fluctuate a lot when Quantum BioPharma's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Quantum BioPharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Quantum because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Quantum BioPharma after-hype prediction price | USD 3.73 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Quantum |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Quantum BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Quantum BioPharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Quantum BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Quantum BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Quantum BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Quantum BioPharma Estimiated After-Hype Price Volatility
In the context of predicting Quantum BioPharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Quantum BioPharma's historical news coverage. Quantum BioPharma's after-hype downside and upside margins for the prediction period are 0.19 and 11.75, respectively. We have considered Quantum BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Quantum BioPharma is very risky at this time. Analysis and calculation of next after-hype price of Quantum BioPharma is based on 3 months time horizon.
Quantum BioPharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Quantum BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Quantum BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Quantum BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.27 | 8.02 | 0.28 | 0.08 | 2 Events / Month | 5 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
4.01 | 3.73 | 6.98 |
|
Quantum BioPharma Hype Timeline
Quantum BioPharma is at this time traded for 4.01. The entity has historical hype elasticity of -0.28, and average elasticity to hype of competition of -0.08. Quantum is anticipated to decline in value after the next headline, with the price expected to drop to 3.73. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -6.98%, whereas the daily expected return is at this time at 0.27%. The volatility of related hype on Quantum BioPharma is about 2623.36%, with the expected price after the next announcement by competition of 3.93. About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.55. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Quantum BioPharma recorded a loss per share of 13.0. The entity had not issued any dividends in recent years. The firm had 1:65 split on the 15th of August 2024. Given the investment horizon of 90 days the next anticipated press release will be in a few days. Check out Quantum BioPharma Basic Forecasting Models to cross-verify your projections.Quantum BioPharma Related Hype Analysis
Having access to credible news sources related to Quantum BioPharma's direct competition is more important than ever and may enhance your ability to predict Quantum BioPharma's future price movements. Getting to know how Quantum BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Quantum BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| COLL | Collegium Pharmaceutical | (1.52) | 8 per month | 0.00 | (0.19) | 2.95 | (4.47) | 12.29 | |
| PAHC | Phibro Animal Health | (0.12) | 10 per month | 0.00 | (0.05) | 3.42 | (3.00) | 12.19 | |
| ANIP | ANI Pharmaceuticals | 0.69 | 10 per month | 0.00 | (0.05) | 2.64 | (3.64) | 9.65 | |
| PROC | Procaps Group SA | (0.48) | 4 per month | 10.18 | 0.08 | 38.04 | (18.67) | 122.49 | |
| RGC | Regencell Bioscience Holdings | (0.73) | 10 per month | 5.87 | 0.03 | 19.02 | (10.93) | 43.32 | |
| LFCR | Lifecore Biomedical | (0.17) | 7 per month | 3.75 | 0.16 | 9.76 | (5.78) | 24.59 | |
| PTPI | Petros Pharmaceuticals | 0.19 | 3 per month | 7.22 | 0.06 | 20.51 | (14.29) | 115.19 |
Quantum BioPharma Additional Predictive Modules
Most predictive techniques to examine Quantum price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Quantum using various technical indicators. When you analyze Quantum charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Quantum BioPharma Predictive Indicators
The successful prediction of Quantum BioPharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Quantum BioPharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Quantum BioPharma based on analysis of Quantum BioPharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Quantum BioPharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Quantum BioPharma's related companies.
Story Coverage note for Quantum BioPharma
The number of cover stories for Quantum BioPharma depends on current market conditions and Quantum BioPharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Quantum BioPharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Quantum BioPharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Quantum BioPharma Short Properties
Quantum BioPharma's future price predictability will typically decrease when Quantum BioPharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Quantum BioPharma often depends not only on the future outlook of the potential Quantum BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Quantum BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 605.8 K |
Check out Quantum BioPharma Basic Forecasting Models to cross-verify your projections. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quantum BioPharma. If investors know Quantum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quantum BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quantum BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quantum BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quantum BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.